| A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. | |
| | |
MedLine Citation:
|
PMID: 16923414 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND AIM: Despite major advances in the treatment of heart failure, cardiogenic shock (CGS) remains associated with substantial mortality. Recent data suggest that the TandemHeart percutaneous ventricular assist device (pVAD) may be useful in the management of CGS. The aim of this prospective randomized study was to test the hypothesis that the TandemHeart (pVAD) provides superior hemodynamic support compared with intraaortic balloon pumping (IABP). METHODS: Forty-two patients from 12 centers presenting within 24 hours of developing CGS were included in the study and treated in an initial roll-in phase (n = 9) or randomized to treatment with IABP (n = 14) or TandemHeart pVAD (n = 19). Thirty patients (71%) had persistent CGS despite having an IABP in place at the time of study enrollment. RESULTS: Cardiogenic shock was due to myocardial infarction in 70% of the patients and decompensated heart failure in most of the remaining patients. The mean duration of support was 2.5 days. Compared with IABP, the TandemHeart pVAD achieved significantly greater increases in cardiac index and mean arterial blood pressure and significantly greater decreases in pulmonary capillary wedge pressure. Overall 30-day survival and severe adverse events were not significantly different between the 2 groups. CONCLUSION: In patients presenting within 24 hours of the development of CGS, TandemHeart significantly improves hemodynamic parameters, even in patients failing IABP. Larger-scale studies are required to assess the influence of improved hemodynamics on survival. |
| | |
Authors:
|
Daniel Burkhoff; Howard Cohen; Corinna Brunckhorst; William W O'Neill; |
Related Documents
:
|
2804784 - Clinical experience with percutaneous intra-aortic balloon pumping in cardiogenic shock... 626124 - Progressive nature of myocardial injury in selected patients with cardiogenic shock. 17481944 - Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunc... 9491944 - Cardiogenic shock: therapy and prevention. 2239654 - Persistent uptake of indium-111-antimyosin monoclonal antibody in patients with myocard... 15887474 - Urgent need to reorganize heart failure management: from paradoxes to heart failure cli... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American heart journal Volume: 152 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-08-22 Completed Date: 2006-09-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 469.e1-8 Citation Subset: AIM; IM |
Affiliation:
|
Cardiovascular Research Foundation, Orangeburg, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Equipment Safety / instrumentation Female Heart-Assist Devices / adverse effects* Humans Intra-Aortic Balloon Pumping / adverse effects*, instrumentation* Male Middle Aged Prospective Studies Shock, Cardiogenic / mortality*, surgery* Treatment Outcome |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sex and classic risk factors after myocardial infarction: a community study.
Next Document: Myocardial perfusion in apical ballooning syndrome correlate of myocardial injury.